BPC-157 and the Peptide Compounding Fight: Where Things Stand in October 2026
Three things moved this year and none made BPC-157 legal to compound. The dates, the votes and the pending policy, explained.
Direct answer
As of October 15, 2026, BPC-157 has no lawful route into a U.S. 503A compounding pharmacy: it is not FDA-approved, not on the 503A bulks list and not in FDA’s interim Category 1. FDA moved it out of Category 2 in April, an advisory committee voted 8–6 for it in July, and an interim access policy reached White House review on October 14.
None of the three changed the law: the vote is advisory, the April move followed a withdrawn nomination, and the policy is unpublished.
What changed in 2026, in order
These events sit on different legal tracks, and only the pending policy could change what a pharmacy may do soon.
| Date | Event | Source | What it changed |
|---|---|---|---|
| Apr 15–22, 2026 | FDA removes 12 peptides from the 503A Category 2 list after their nominators withdraw; BPC-157 now sits in a “nominated but withdrawn” table | FDA safety-risks page (current 04/22/2026); announcement date reported by Orrick | Removed a safety flag, granted no permission |
| May 14, 2026 | Non-injectable GHK-Cu returns to Category 1; FDA says it will consult the committee on GHK-Cu before the end of February 2027 | FDA categories list | Topical GHK-Cu regains interim eligibility |
| Jul 23–24, 2026 | Committee votes: BPC-157, KPV and TB-500 8–6–1 in favor; MOTS-c 7–5–2; Semax 8–5; Epitalon 7–5–1; DSIP 6–7–1 against | FDA meeting page; tallies press-reported | Advice to FDA; not binding |
| Aug 12 and Oct 8, 2026 | Eli Lilly files eleven lawsuits against retatrutide sellers, including peptide vendors and a pharmacy | Court dockets | Civil action against sellers |
| Aug 24, 2026 | FDA warning letters to five “research use only” peptide sellers (FDA pages dated Sept 1) | FDA warning letters, e.g. 735063 | RUO labels rejected as a defence |
| Oct 1, 2026 | FDA: retatrutide and cagrilintide “cannot be used in compounding under federal law” | FDA GLP-1 page | Restates the law |
| Oct 14, 2026 | OMB receives FDA’s “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94, stage: notice) | OIRA review list, run Oct 15 | Pending; contents not public |
Is BPC-157 legal to compound right now?
No. A 503A pharmacy may compound from a bulk substance only if it has a USP monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list; FDA’s interim policy also tolerates Category 1 substances while they are evaluated. BPC-157 meets none of those tests as of October 15, 2026.
The April change is often misread. FDA did not clear BPC-157. Its nominator withdrew the nomination, so FDA moved it from Category 2 into a separate table of withdrawn nominations. That table still carries FDA’s safety language: compounded BPC-157 “may pose risk for immunogenicity”, may have problems with peptide-related impurities, and FDA “lacks sufficient information to know whether the drug would cause harm when administered to humans.” A substance on no list has no interim safe harbor at all, which is a weaker position than Category 1, not a stronger one.
The same applies to TB-500, KPV, MOTS-c, Semax, Epitalon, DSIP, CJC-1295 and injectable GHK-Cu. See our BPC-157 evidence page and peptide legality guide; earlier pages that called BPC-157 “Category 2” are fixed in the corrections log.
Peptide by peptide: where each one stands
Four questions that marketing pages merge, kept apart. Evidence tiers follow our peptide evidence map.
| Peptide | FDA-approved product | 503A compounding status | July 2026 committee (reported) | WADA 2026 list | Human efficacy trials |
|---|---|---|---|---|---|
| BPC-157 | None | Nomination withdrawn; on no list | 8–6–1 for, ulcerative colitis only | Prohibited (S0) | None published |
| TB-500 | None | Nomination withdrawn; on no list | 8–6–1 for, wound healing | Prohibited (S2.3) | None identified by FDA staff |
| KPV | None | Nomination withdrawn | 8–6–1 for, wound healing and inflammation | — | No human exposure data identified by FDA |
| MOTS-c | None | Nomination withdrawn | 7–5–2 for, obesity and osteoporosis | Prohibited (S4.4.1) | None |
| Semax | None in the U.S. | Nomination withdrawn | 8–5 for, cerebral ischemia, migraine, trigeminal neuralgia | — | Limited |
| Epitalon | None | Nomination withdrawn | 7–5–1 for, insomnia (some outlets report 7–4–1) | — | None |
| DSIP (emideltide) | None | Nomination withdrawn | 6–7–1 against | — | Limited |
| GHK-Cu | None | Category 1 for non-injectable routes; injectable withdrawn | Not reviewed; review due by Feb 2027 | — | Limited, mostly topical |
| CJC-1295 | None | Nomination withdrawn | Not reviewed | Prohibited (S2.2.4) | Limited |
| Ipamorelin | None | 503A nomination withdrawn; 503B Category 2 | Not reviewed | Prohibited (S2.2.4) | One phase 2 trial (postoperative ileus) missed its endpoint |
| Kisspeptin-10 | None | Category 2 (503A) | Not reviewed | Prohibited (S2.2.1) | Limited |
| Sermorelin | Geref, discontinued (not for safety reasons) | Generally eligible as a component of an approved drug (our analysis) | Not reviewed | Prohibited (S2.2.4) | Historical approval |
| Tesamorelin | Egrifta SV and WR (HIV lipodystrophy) | Approved biologic | Not reviewed | Prohibited (S2.2.4) | Yes, for the labeled use |
| Bremelanotide (PT-141) | Vyleesi | Approved drug | Not reviewed | — | Yes, for the labeled use |
| NAD+ and glutathione | None as peptide therapies | Category 1 | Not reviewed | — | Limited for marketed uses |
Vote tallies are press-reported (Pharmaceutical Executive, AJMC, RAPS); FDA had posted no minutes as of October 15, 2026.
What did the July advisory vote actually decide?
It decided nothing on its own. The Pharmacy Compounding Advisory Committee advises FDA; every one of the seven FDA briefing documents concluded that “the evaluation criteria weigh against” listing, and the committee disagreed on six of seven.
Three details matter. First, each vote was indication-specific. BPC-157 was reviewed for ulcerative colitis, not for tendon, joint or sports recovery, which is where nearly all of its consumer marketing sits. Second, the nominators had withdrawn all seven nominations before the meeting; FDA chose to present them anyway. Third, the committee voted twice per peptide, on the free base and on the acetate salt, and the public tallies do not say whether the two counts matched.
A listing for ulcerative colitis would not cover a knee or shoulder prescription. Keep that gap in mind when a clinic cites the vote.
The interim access policy: what is known and what is not
On October 14, 2026, the White House regulatory office logged an FDA item titled “Interim Access Policy for Compounding Using Certain Peptides” (RIN 0910-ZD94) at the “notice” stage. It names no substances. The Associated Press, citing two people familiar with the plan, reports that it would let pharmacies temporarily compound popular peptides, including BPC-157, through enforcement discretion rather than rulemaking. The Washington Post and Pink Sheet report opposition from FDA career staff; we could not read either article in full.
Until FDA publishes the notice, nobody knows which peptides it covers, for which uses, under what quality conditions or for how long. Enforcement discretion is not approval.
What this means for you
If you are offered BPC-157, TB-500 or a similar peptide today, there is still no lawful 503A route: the product is compounded outside the rules or sold as a “research” chemical. FDA’s August 24 letters said a research-use-only label does not stop a product being a drug when the seller’s site shows it is meant for people.
Worked example 1: the price of a peptide with no trial. The only public prescription price we found for BPC-157 on October 15 was $399 a month plus a processing fee, at a single Arizona practice. Twelve months is $399 × 12 = $4,788 before the fee, for a substance with no published human efficacy trial for any use.
Worked example 2: the same budget on a peptide with trials. If the goal is weight loss, the peptides with phase 3 evidence are GLP-1s. NexLife’s compounded semaglutide is $119 a month on its 12-month plan: $119 × 12 = $1,428, or $3,360 less than the BPC-157 year above. Eden’s flat $99 a month is $1,188 a year. Compounded semaglutide is not FDA-approved either, but its active ingredient has trial data in the approved product and a lawful 503A route.
Worked example 3: athletes. BPC-157 is named on WADA’s 2026 Prohibited List under S0 and TB-500 under S2.3, both prohibited at all times. A prescription does not change that.
Before paying anyone for a peptide, run the checks in our peptide provider verification guide and read how research peptides differ from prescription products.
Sources
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (current 04/22/2026) read October 15, 2026
- FDA: Bulk drug substances used in compounding under section 503A, categories list (updated May 14, 2026) read October 15, 2026
- FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting page read October 15, 2026
- FDA briefing document: BPC-157 read October 15, 2026
- Federal Register 91 FR 20465 (April 16, 2026), docket FDA-2025-N-6895 read October 15, 2026
- OIRA: rules under review (RIN 0910-ZD94, received Oct 14, 2026) read October 15, 2026
- FDA warning letter 735063, Peptide Partners LLC (Aug 24, 2026) read October 15, 2026
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current 10/01/2026) read October 15, 2026
- Eli Lilly v. Legendary Peptides, LLC, E.D. Tex. 1:26-cv-00347 (filed Aug 12, 2026) read October 15, 2026
- Orrick: FDA announces removal of 12 peptides from Category 2 (April 2026) read October 15, 2026
- STAT / Associated Press: administration advances peptide plan (Oct 15, 2026) read October 15, 2026
- NexLife: compounded semaglutide plans (read Oct 15, 2026) read October 15, 2026
Frequently asked questions
Is BPC-157 legal in the United States in October 2026?
It is not FDA-approved and, as of October 15, 2026, it has no lawful route into 503A compounding: it is not on the 503A bulks list or in Category 1.
Did the FDA approve BPC-157 in July 2026?
No. An FDA advisory committee voted 8-6 with one abstention to recommend adding BPC-157 to the 503A bulks list for ulcerative colitis. The vote is advice to FDA, FDA staff had recommended against, and no listing has been proposed or finalized.
Is BPC-157 still on FDA Category 2?
No. FDA moved BPC-157 out of Category 2 in April 2026 after its nomination was withdrawn. It now sits in a table of withdrawn nominations that keeps FDA’s safety concerns, and it did not move into Category 1, so it gained no permission.
What is the FDA interim access policy for peptides?
An FDA notice that reached White House review on October 14, 2026. Its text is not public; press reports say it would allow temporary compounding of some peptides, possibly BPC-157, through enforcement discretion.
Can athletes use BPC-157 or TB-500 with a prescription?
No. The WADA 2026 Prohibited List names BPC-157 under S0 and TB-500 under S2.3, prohibited at all times. A prescription does not alter anti-doping rules.